The Soluble Plasminogen Activator Receptor as a Biomarker on Monitoring the Therapy Progress of Pulmonary TB-AFB(+) Patients
Table 2
Comparison between medical records used to monitor TB theraphy progress in Indonesia, that is, patients complaints, BMI (kg/m2), width of lesion, sputum AFB, erythrocyte sedimentation rate (mm/hour), monocyte count (cell/mm2), and soluble urokinase plasminogen activator receptor during the 6-month therapy.
During anti-TB-drugs treatment
No.
Medical records and level of suPAR
Before Treatment
2 months
4 months
6 months
-value .05
1
Patients’ Complaints
Chronic cough 3 weeks
20 (100%)
17 (85%)
5 (25%)
Decrease of appetite
15 (75%)
0 (0%)
0 (0%)
Low grade fever
10 (50%)
0 (0%)
0 (0%)
Shortness of breath
9 (45%)
5 (25%)
3 (15%)
Hemoptoe
9 (45%)
0 (0 %)
0(0 %)
Chest pain
2 (10 %)
1 (5 %)
1 (5 %)
2
BMI
18.28 2.12
19.18 2.31
20.36 2.35
.0001
3
Width of lesion classification
Thoracic Imaging
Thoracic Imaging
Minimal Lesion Mod Advance Lesion Far Advance Lesion